Rheumatology Therapeutics Market to Hit a Valuation of US$ 38.34 Billion by 2033 | Astute Analytica
View original at globenewswire.com“Quarterly results validate this aggressive outlook, as Skyrizi generated USD 4.7 billion in absolute revenue during Q3 2024, while Rinvoq contributed USD 2.2 billion.”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The median annual cost for biologics facing biosimilar competition has dropped to USD 23,700
80% confidenceProjections for 2025 warn of a deficit of 2,576 adult rheumatologists needed to match patient volume
80% confidenceAbbVie has officially confirmed guidance of USD 16.5 billion in global sales for Skyrizi alone in 2025
80% confidenceEast and South Asia reported a staggering 4.8 million diagnosed rheumatoid arthritis cases in 2024
80% confidenceBiosimilar prescriptions surged to account for nearly 1 in 4 adalimumab scripts, totaling approximately 250,000 following CVS Caremark formulary removal of Humira
80% confidenceRevenue guidance for Rinvoq has been raised to USD 8.2 billion for 2025
80% confidenceThe average annual cost for Medicare patients on biologics stood at USD 36,053 in 2024
80% confidenceThe global rheumatology therapeutics market was valued at US$ 28.75 billion in 2024 and is expected to reach US$ 38.34 billion by 2033, witnessing a CAGR of 3.4% during the forecast period 2025-2033
80% confidenceThe Asia-Pacific region tracks 3.2 million RA cases
80% confidence72 out of every 100 US counties have zero clinically active rheumatologists
80% confidenceVagus Nerve Stimulation trial reported 35 out of 100 patients achieving statistically significant responses
80% confidence78 million Americans will carry an arthritis diagnosis by 2040
80% confidenceUninsured or unresponsive patients face up to USD 30,000 annually in out-of-pocket costs
80% confidenceMainland China accounted for 58 of every 100 new rheumatology trials initiated in 2024
80% confidenceBiologics without biosimilar competition maintain a median cost of USD 42,527
80% confidence87 patients achieved substantial ACR50 improvement in ivarmacitinib trial compared to just 29 in the placebo group
80% confidenceMore than 75 key pharmaceutical companies have registered active clinical programs in 2024 alone
80% confidenceOver 80 distinct therapies for rheumatoid arthritis are currently in active development pipelines
80% confidence18 million new cases of rheumatoid arthritis were identified globally in 2024
80% confidence59 out of 100 patients on Abatacept achieved ACR50 in the AMPLIFIED trial, demonstrating efficacy on par with Adalimumab
80% confidenceThe Sandoz-produced adalimumab-adaz captured 55.5% of all biosimilar prescriptions
80% confidenceWhile 29 out of 100 high-risk placebo patients developed RA, only 9 out of 100 in the methotrexate treatment arm progressed to the disease
80% confidenceOver a five-year span, the average sales price of rheumatology biosimilars has decreased by USD 2,200
80% confidenceThe US currently relies on just 5,667 clinically active rheumatologists
80% confidenceIn the IVARMACITINIB trial, 133 out of 189 patients successfully achieved an ACR20 response
80% confidence93 out of 100 rural jurisdictions lack a single rheumatology provider
80% confidenceHigh-dose arms of major 2024 JAK-1 inhibitor trials reported 0 systemic opportunistic infections
80% confidenceNorth America holds 41% of the global rheumatology therapeutics revenue share
80% confidenceSkyrizi and Rinvoq together are targeted to exceed USD 25 billion in sales in 2025, effectively surpassing the historical peak revenues of Humira
80% confidence50% of the current rheumatology workforce is aged over 55, signaling an impending retirement cliff
80% confidence